Neogenomics News

News

0

Ticker

NEO

ISIN

US64049M2098

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Neogenomics Eulerpool News

9/19/2025, 7:07:57 AM

Kassensturz bei Cash-Burnern: Welche Aktien Anleger meiden sollten

Reality check for cash-burners: Which stocks investors should avoid

9/12/2025, 6:40:49 AM

Anlagestrategien in Zeiten der Unsicherheit: Auf der Suche nach Stabilität und Rendite

Investment Strategies in Times of Uncertainty: In Search of Stability and Return

9/10/2025, 9:46:21 PM

Marktanalyse: Natera im Fokus nach Innovationsvorstoß von Exact Sciences

Market Analysis: Natera in Focus After Innovation Push by Exact Sciences

10/23/2024, 5:23:57 PM

NeoGenomics erhält grünes Licht für innovative Tumor-Diagnosetests in New York

NeoGenomics Receives Green Light for Innovative Tumor Diagnostic Tests in New York

Neogenomics Stock News

Neogenomics is being monitored by journalists and investors worldwide. We gather the latest Neogenomics news here.

September 23·
Yahoo
3 Healthcare Stocks We’re Skeptical Of
September 22·
Yahoo
NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?
September 21·
Yahoo
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
September 18·
Yahoo
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
September 15·
SeekingAlpha
NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
February 17·
ChartMill
NeoGenomics Inc (NASDAQ:NEO) Beats Q4 Earnings Estimates and Provides 2026 Guidance
February 17·
SeekingAlpha
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
February 17·
SeekingAlpha
NeoGenomics, Inc. 2025 Q4 - Results - Earnings Call Presentation
February 17·
Benzinga
NeoGenomics Sees FY2026 Sales $793.000M-$801.000M vs $795.995M Est
February 17·
Benzinga
NeoGenomics Earnings Report: Q4 Overview
February 17·
Benzinga
NeoGenomics Q4 Adj. EPS $0.06 Beats $0.04 Estimate, Sales $190.170M Beat $188.049M Estimate
February 17·
Benzinga
Earnings Scheduled For February 17, 2026
February 12·
Benzinga
NeoGenomics Announced The Availability Of Pantracer Pro, A New Addition To The Pantracer Family, Designed To Help Clinicians Navigate Increasingly Complex Molecular Testing Workflows To Make Informed Decisions For Patients With Advanced-stage Solid Tumors
January 25·
SeekingAlpha
NeoGenomics: Distribution Moat In Community Oncology
January 14·
SeekingAlpha
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 12·
Benzinga
NeoGenomics Sees Q4 Sales $190.000M vs $188.260M Est
January 6·
Yahoo
A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift
December 30·
Yahoo
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors
December 18·
Yahoo
3 Russell 2000 Stocks We Think Twice About
December 17·
Yahoo
3 Stocks Under $50 We Steer Clear Of

Neogenomics Stock Press Releases

Neogenomics regularly publishes news on the company's website that are relevant for investors.

November 21•
Neogenomics
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
November 18•
Neogenomics
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
November 8•
Neogenomics
NeoGenomics Reports Third Quarter 2022 Results
November 7•
Neogenomics
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
October 28•
Neogenomics
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
October 13•
Neogenomics
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
September 7•
Neogenomics
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
August 16•
Neogenomics
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 9•
Neogenomics
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
July 21•
Neogenomics
NeoGenomics Announces Chief Executive Officer Appointment
July 15•
Neogenomics
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
June 21•
Neogenomics
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
June 3•
Neogenomics
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
June 3•
Neogenomics
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
May 16•
Neogenomics
NeoGenomics Appoints Lynn Tetrault Interim CEO
May 10•
Neogenomics
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
May 9•
Neogenomics
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
May 5•
Neogenomics
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
April 27•
Neogenomics
NeoGenomics Reports Revenue of $117 Million in the First Quarter
April 25•
Neogenomics
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
April 11•
Neogenomics
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
April 11•
Neogenomics
Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D
April 11•
Neogenomics
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
April 8•
Neogenomics
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
March 28•
Neogenomics
NeoGenomics Announces CEO Departure and Initiates CEO Search
March 17•
Neogenomics
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
March 2•
Neogenomics
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
February 23•
Neogenomics
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
February 14•
Neogenomics
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
February 11•
Neogenomics
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

Neogenomics News 2026

This page contains all current news, analysis and press releases for Neogenomics stock (NEO, ISIN: US64049M2098). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Neogenomics.

Neogenomics Stock

Neogenomics Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients.